|
INTERVIEW
Good Science And The Marketplace For Drugs: A Conversation With Jean-Pierre Garnier
John K. Iglehart
| The first 100 words of the full text of this article appear below. |
|
A Medicare Prescription Drug Benefit
|
|---|
John Iglehart: GlaxoSmithKliney has evolved through mergers and acquisitions into the second-largest pharmaceutical company in the world, with annual revenues of $32 billion and pretax profits last year of $10 billion. While I plan to explore with you some of the industry and international issues that face your company, I would like to begin by asking you about a subject that is of consuming interest to the U.S. health policy community. Should the Medicare program, which pays most of the acute care medical expenses of some forty million disabled and elderly Americans, expand the scope of its prescription drug benefit? . . . [Full Text of this Article]
|
Challenges Of A Generic Market
|
|---|
|
Drug Prices Around The World
|
|---|
|
Cost-Effectiveness Analysis
|
|---|
|
Future Of Developing New Drugs
|
|---|
|
Opening Up The Developing World
|
|---|
|
Vaccines For Infectious Diseases
|
|---|
|
HIV/AIDS Initiatives In Africa
|
|---|
|
Imperatives For Health Care Systems Worldwide
|
|---|
       What's this?
This article has been cited by other articles:
|
|
|
|
 
B. Spitz and J. Abramson
When Health Policy Is the Problem: A Report from the Field
Journal of Health Politics Policy and Law,
June 1, 2005;
30(3):
327 - 366.
[Abstract]
[PDF]
|
|
|
|
